Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 32Leukemia, Lymphocytic, Chronic, B-Cell 22Myelodysplastic Syndromes 9Lymphoma, Follicular 8Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Recurrence 5Leukemia, Myelomonocytic, Chronic 5Multiple Myeloma 4Chromosome 17 deletion 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid 3Hematologic Neoplasms 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Breast Neoplasms 2Tumor Lysis Syndrome 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myeloid Malignancy 1Myeloid Malignancies 1

Interventions

venetoclax 1eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloid Malignancy × venetoclax × Clear all
NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡